The FDA has granted fast track designation to AVB-001 for the treatment of adult patients with relapsed/refractory, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
/PRNewswire/ Avenge Bio, Inc., a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune.